Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

AIDS

Volumn 18, Issue 6, 2004, Pages 887-895

  Coetzee, David ^a,b   Hildebrand, Katherine ^a   Boulle, Andrew ^a   Maartens, Gary ^b   Louis, Francoise ^c   Labatala, Veliswa ^c   Reuter, Hermann ^c   Ntwana, Nonthutuzelo ^c   Goemaere, Eric ^c  

^a School of Public Health and Family Medicine   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Antiretroviral therapy; CD4 cell count; HIV RNA viral load; Primary care; South africa

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOUTH AFRICA; SURVIVAL; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTI-HIV AGENTS; COMMUNITY HEALTH SERVICES; DEVELOPING COUNTRIES; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 2142764446     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404090-00006     Document Type: Article

References (24)

1. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
2. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
3. Berkman A. Confronting global AIDS: prevention and treatment. Am J Public Health 2001, 91:1348-1349.
4. Hogg R, Cahn P, Katabira ET, Lange J, Samuel NM, O'Shaughnessy M, et al. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002, 360:1710-1711.
5. Kenyon C, Skordis J, Boulle A, Pillay K. The ART of rationing. S Afr Med J 2002, 93.
6. World Health Organization. Scaling up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach. Geneva: WHO; 2002.
7. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002, 360:34-40.
8. Darkoh-Ampem, E, Obita, G, De Korte D, Mazonde P. Scaling up antiretroviral therapy in a resource-poor setting: Botswana example. International Conference on HIV Therapy. Edinburgh, month? 2002 [abstract Pl4.3].
9. Dorrington R. Population Projections for the Western Cape to 2025. Cape Town, South Africa: Centre for Actuarial Research, University of Cape Town; 2002.
10. South African Census 1996, as provided by voting ward by the Municipal Demarcation Board. http://www.dermarcation.org.za. Accessed 30-9-2002.
11. Antenatal HIV and Syphilis Prevalence Survey. Cape Town, South Africa: Department of Health, Western Cape; 2001.
12. City of Cape Town Department of Health. Tuberculosis Service Review, Khayelitsha Health District. Cape Town, South Africa: Department of Health; 2002.
13. Abdullah MF, Young T, Bitalo L, Coetzee N, Myers JE. Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha. S Afr Med J 2001, 91:579-583.
14. Acquired Immune Deficiency Syndrome: Interim proposal for a WHO Staging System for HIV Infection and Disease. Weekly Epidemiol Rec 1990, 65:221-224.
15. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Morb Mortal Wkly Rep 2000, 49:185-189.
16. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002, 16:1363-1370.
17. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med 1996, 89:505-508.
18. Chan KC, Yip B, Hogg RS, Montaner JS, O'Shaughnessy MV. Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 2002, 16:1693-1695.
19. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17:1369-1375.
20. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
21. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000, 14:1171-1180.
22. Smith D, Berrey MM, Robertson M, Mehrotra D, Markowitz M, Perrin L, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000, 182:950-954.
23. Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003, 17:963-969.
24. d'Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000, 14:499-507.